Anti-β-glucan antibody in bovine sera

International Journal of Medicinal Mushrooms

Volumn 7, Issue 4, 2005, Pages 513-524

  Ishibashi, Ken Ichi ^a   Dogasaki, Chikaku ^b   Iriki, Tsunenori ^b   Motoi, Masuro ^a   Kurone, Yu Ichiro ^a   Miura, Noriko N ^a   Adachi, Yoshiyuki ^a   Ohno, Naohito ^a  

^a TOKYO UNIVERSITY OF PHARMACY AND LIFE SCIENCES   (Japan)

^b AZABU UNIVERSITY   (Japan)

Author keywords

glucan; Agaricus brasiliensis; Anti BG antibody; Bovine sera; Medicinal mushrooms

Indexed keywords

ANTIBODY; BETA 1,3 GLUCAN; BETA 1,6 GLUCAN; BETA GLUCAN; BETA GLUCAN ANTIBODY; GRIFOLAN; IMMUNOGLOBULIN G ANTIBODY; LIPOPOLYSACCHARIDE; MANNAN; POLYSACCHARIDE; SCHIZOPHYLLAN; UNCLASSIFIED DRUG;

AGARICUS; AGARICUS BRASILIENSIS; AGE; ALCALIGENES FAECALIS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY DETECTION; ANTIBODY SPECIFICITY; ANTIBODY TITER; ANTIGEN ANTIBODY COMPLEX; ANTIGEN RECOGNITION; ARTICLE; ASPERGILLUS; BIOLOGICAL ACTIVITY; CANDIDA; CANDIDA ALBICANS; CONTROLLED STUDY; COW; CROSS REACTION; EDIBLE MUSHROOM; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; GRIFOLA; IMMUNE RESPONSE; IMMUNOPHARMACOLOGY; IMMUNOREACTIVITY; MALE; MOUSE STRAIN; MUSHROOM; NONHUMAN; SACCHAROMYCES CEREVISIAE; SCHIZOPHYLLUM COMMUNE; SERUM; VOLUNTEER;

AGARICUS; ALCALIGENES FAECALIS; ANIMALIA; ASPERGILLUS; BASIDIOMYCOTA; BOVINAE; CANDIDA; CANDIDA ALBICANS; ESCHERICHIA COLI; GRIFOLA; GRIFOLA FRONDOSA; SACCHAROMYCES CEREVISIAE; SCHIZOPHYLLUM COMMUNE;

EID: 33645514990     PISSN: 15219437     EISSN: None     Source Type: Journal    
DOI: 10.1615/IntJMedMushr.v7.i4.10     Document Type: Article

References (40)

1. Adachi Y., Ohno N., Yadomae T. 1994. Preparation and antigen specificity of an anti-(1→3)-beta-D-glucan antibody. Biol Pharm Bull, 17, 1508-1512.
2. Adachi Y., Ishii T., Ikeda Y., Hoshino A., Tamura H., Aketagawa J., Tanaka S., Ohno N. 2004. Characterization of β-glucan recognition site on C-type lectin, Dectin 1. Infect Immun, 72, 4159-4171.
3. Brown G. D., Gordon S. 2001. Immune recognition. A new receptor for beta-glucans. Nature, 413, 36-37.
4. Chihaya Y., Okada H., Matsukawa K., Matsui Y. 1992. Disseminated mycoses in cattle. A study on nine autopsy cases. J Vet Med Sci, 54, 485-491.
5. Fujimiya Y., Suzuki Y., Oshiman K., Kobori H., Moriguchi K., Nakashima H., Matumoto Y., Takahara S., Ebina T., Katakura R. 1998. Selective tumoricidal effect of soluble proteoglucan extracted from the basidiomycete, Agaricus blazei Murrill, mediated via natural killer cell activation and apoptosis. Cancer Immunol Immunother, 46, 147-159.
6. Fujimoto S., Furue H., Kimura T., Kondo T., Orita K., Taguchi T., Yoshida K., Ogawa N. 1991. Clinical outcome of postoperative adjuvant immunochemotherapy with sizofiran for patients with resectable gastric cancer: a randomised controlled study. Eur J Cancer, 27, 1114-1118.
7. Harada T., Miura N. N., Adachi Y., Nakajima M., Yadomae T., Ohno N. 2003. Antibody to soluble 1,3/1,6-beta-D-glucan, SCG in sera of naïve DBA/2 mice. Biol Pharm Bull, 26, 1225-1228.
8. Iino K., Ohno N., Suzuki I., Sato K., Oikawa S., Yadomae T. 1985. Structure-function relationship of antitumor beta-1,3-glucan obtained from matted mycelium of cultured Grifola frondosa. Chem Pharm Bull (Tokyo), 33, 4950-4956.
9. Ishibashi K., Miura N. N., Adachi Y., Tamura H., Tanaka S., Ohno N. 2004a. The solubilization and biological activities of Aspergillus beta-(1→ 3)-D-glucan. FEMS Immunol Med Microbiol, 42, 155-166.
10. Ishibashi K., Yoshida M., Nakabayashi I., Shinohara H., Miura N. N., Adachi Y., Ohno N. 2005. Interaction of anti-β-glucan antibody and fungal cell wall beta-glucan. FEMS Immunol Med Microbiol, 44, 99-109.
11. Itoh H., Ito H., Amano H., Noda H. 1994. Inhibitory action of a (1→6)-beta-D-glucan-protein complex (F III-2-b) isolated from Agaricus blazei Murill ("himematsutake") on Meth A fibrosarcoma-bearing mice and its antitumor mechanism. Jpn J Pharmacol, 66, 265-271.
12. Jensen H. E. 1994. Systemic bovine aspergillosis and zygomycosis in Denmark with reference to pathogenesis, pathology, and diagnosis. APMIS, Suppl. 42, 1-48.
13. Masuzawa S., Yoshida M., Ishibsahi K., Saito N., Akashi M., Yshikawa N., Suzuki T., Nameda S., Miura N. N., Adachi Y., Ohno N. 2003. Solubilized Candida cell wall β-glucan, CSBG, is epitope of natural human antibody. Drug Develop Res, 58, 179-189.
14. Mimura H., Ohno N., Suzuki I., Yadomae T. 1985. Purification, antitumor activity, and structural characterization of beta-1,3-glucan from Peziza vesiculosa. Chem Pharm Bull (Tokyo), 33, 5096-5099.
15. Motoi M., Ishibashi K., Mizukami O., Miura N. N., Adachi Y., Ohno N. 2004. Anti β-glucan antibody in cancer patients. Int J Med Mushr, 6, 41-48.
16. Ohno N., Suzuki I., Oikawa S., Sato K., Miyazaki T., Yadomae T. 1984. Antitumor activity and structural characterization of glucans extracted from cultured fruit bodies of Grifola frondosa. Chem Pharm Bull (Tokyo), 32, 1142-1151.
17. Ohno N., Iino K., Takeyama T., Suzuki I., Sato K., Oikawa S., Miyazaki T., Yadomae T. 1985. Structural characterization and antitumor activity of the extracts from matted mycelium of cultured Grifola frondosa. Chem Pharm Bull (Tokyo), 33, 3395-3401.
18. Ohno N., Adachi Y., Suzuki I., Oikawa S., Sato K., Ohsawa M., Yadomae T. 1986a. Antitumor activity of a beta-1,3-glucan obtained from liquid cultured mycelium of Grifola frondosa. J Pharmacobiodyn, 9, 861-864.
19. Ohno N., Suzuki I., Yadomae T. 1986b. Structure and antitumor activity of a beta-1,3-glucan isolated from the culture filtrate of Sclerotinia sclerotiorum IFO 9395. Chem Pharm Bull (Tokyo), 34, 1362-1365.
20. Ohno N. Yadomae T. 1996. Structure-activity relationship of immunomodulating (1→3)-β-D-glucans. Recent Res Devel Chem Pharm Sci, 1, 23-33.
21. Ohno N., Miura T., Miura N. N., Chiba N., Uchiyama M., Adachi Y., Yadomae T. 1999a. Inflammatory and immunopharmacological activities of metaperiodate oxidized zymosan. Zentralbl Bakteriol, 289, 63-77.
22. Ohno N., Uchiyama M., Tsuzuki A., Tokunaka K., Miura N. N., Adachi Y., Aizawa M. W., Tamura H., Tanaka S., Yadomae T. 1999b. Solubilization of yeast cell-wall beta-(1→3)-D-glucan by sodium hypochlorite oxidation and dimethyl sulfoxide extraction. Carbohydr Res, 316, 161-172.
23. Ohno N., Miura N. N., Nakajima M., Yadomae T. 2000. Antitumor 1,3-beta-glucan from cultured fruit body of Sparassis crispa. Biol Pharm Bull, 23, 866-872.
24. Ohno N., Furukawa M., Miura N. N., Adachi Y., Motoi M., Yadomae T. 2001a. Antitumor beta glucan from the cultured fruit body of Agaricus blazei. Biol Pharm Bull, 24, 820-828.
25. Ohno N., Miura T., Miura N. N., Adachi Y., Yadomae T. 2001b. Structure and biological activities of hypochlorite oxidized zymosan. Carbohydr Polym, 44, 339-349.
26. Osaki Y., Kato T., Yamamoto K., Okubo J., Miyazaki T. 1994. Antimutagenic and bactericidal substances in the fruit body of a basidiomycete Agaricus blazei, Jun-17. Yakugaku Zasshi, 114, 342-350.
27. Pier A. C., Cabanes F. J., Chermette R., Ferreiro L., Guillot J., Jensen H. E., Santurio J. M. 2000. Prominent animal mycoses from various regions of the world. Med Mycol, 38, Suppl 1, 47-58.
28. Rios-Hernandez M., Dos-Santos N. J., Silvia-Cardoso, Bello-Garciga J. L., Pedroso M. 1994. Immunopharmacological studies of beta-1,3-glucan Arch Med Res, 25, 179-180.
29. Ross G. D., Cain J. A., Myones B. L., Newman S. L., Lachmann P. J. 1987. Specificity of membrane complement receptor type three (CR3) for beta-glucans. Complement, 4, 61-74.
30. Saito K., Nishijima M., Ohno N., Yadomae T., Miyazaki T. 1992. Structure and antitumor activity of the less-branched derivatives of an alkali-soluble glucan isolated from Omphalia lapidescens. (Studies on fungal polysaccharide. XXXVIII). Chem Pharm Bull (Tokyo), 40, 261-263.
31. Shinohara H., Ohno N., Yadomae T. 1988. Antitumor activity and structural characterization of a (1-3)-beta-D-glucan extracted with cold alkali from sclerotia of Sclerotinia sclerotiorum IFO 9395. Chem Pharm Bull (Tokyo), 36, 819-823.
32. Stone B. B., Clarke A. E. 1992. Chemistry and biology of (1→3)-β-glucans. La Trobe University Press, Australia.
33. Taguti T. 1987. Clinical efficacy of lentinan on patients with stomach cancer: end point results of a four-year follow-up survey. Cancer Detect Prev Suppl, 1, 333-349.
34. Thornton, B. P., Vetvicka V., Pitman M., Goldman R. C., Ross G. D. 1996. Analysis of the sugar specificity and molecular location of the beta-glucan-binding lectin site of complement receptor type 3 (CD11b/CD18). J Immunol, 156, 1235-1246.
35. Tielen M. J. 1987. Pathogen supply modified by environment and stage of production Tijdschr Diergeneeskd, 112, 1005-1011.
36. Van den Eynde B. J., van der Bruggen P. 1997. T cell defined tumor antigens. Curr Opin Immunol, 9, 684-693.
37. Wakshull E., Brunke-Reese D., Lindermuth J., Fisette L., Nathans R. S., Crowley J. J., Tufts J. C., Zimmerman J., Mackin W., Adams D. 1999. PGG-glucan, a soluble beta-(1,3)-glucan, enhances the oxidative burst response, microbicidal activity, and activates an NF-kappa B-like factor in human PMN: evidence for a glycosphingolipid beta-(1,3)-glucan receptor. Immunopharmacology, 41, 89-107.
38. Willment J. A., Gordon S., Brown G. D. 2001. Characterization of the human β-glucan receptor and its alternatively spliced isoforms. J Biol Chem, 276, 43818-43823.
39. Yadomae T. 2000. Structure and biological activities of fungal beta-1,3-glucans. Yakugaku Zasshi, 120, 413-431.
40. Zimmerman, J. W., Lindermuth J., Fish P. A., Palace G. P., Stevenson T. T., DeMong D. E. 1998. A novel carbohydrate-glycosphingolipid interaction between a beta-(1-3)-glucan immunomodulator, PGG-glucan, and lactosylceramide of human leukocytes. J Biol Chem, 273, 22014-20.